



Pre-hepatic and pre-pancreatic transplant donor evaluation

Alexis M. Cahalane¹, Amirkasra Mojtahed¹, Dushyant V. Sahani¹, Nahel Elias², Avinash R. Kambadakone¹

¹Division of Abdominal Imaging, Department of Radiology, ²Division of Transplant Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA

Contributions: (I) Conception and design: AM Cahalane, AR Kambadakone; (II) Administrative support: AM Cahalane, AR Kambadakone; (III) Provision of study materials or patients: AM Cahalane, A Mojtahed, AR Kambadakone; (IV) Collection and assembly of data: All data was collected and assembled by AM Cahalane, AR Kambadakone; (V) Data analysis and interpretation: AM Cahalane, AR Kambadakone; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Alexis M. Cahalane, MB, BCh, BAO. Division of Abdominal Imaging, Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Email: acahalane@mgh.harvard.edu.

Abstract: Innovations in surgical techniques coupled with advances in medical and pharmacological management in the past few decades have enabled organ transplantation to become integral to the management of end stage organ failure. In this review article, we will review the role of the radiologist in the work up of liver and pancreas donors during evaluation of their donor candidacy. The critical role of imaging in assessing the parenchymal, biliary and vascular anatomy in liver donor candidates will be reviewed, as well as highlighting the anatomical findings that may pose a contraindication to transplantation. The limited role of imaging in pancreas donor evaluation is also covered, as well as a brief overview of the surgical techniques available and how the radiologist's findings influence operative technique selection.

Keywords: Transplant; transplantation; liver; pancreas; computed tomography; magnetic resonance imaging; vascular

Submitted Jul 21, 2018. Accepted for publication Sep 25, 2018.

doi: [10.21037/cdt.2018.09.14](https://doi.org/10.21037/cdt.2018.09.14)

View this article at: <http://dx.doi.org/10.21037/cdt.2018.09.14>

Introduction

The first successful solid organ transplant in humans was performed by Harrison and Murray in 1954, between two identical twins (1). Subsequent work on immunosuppression in the three decades after 1950 revolutionized the area of transplantation, facilitating the work of Starzl when he completed the first successful liver transplant (LT) in 1967 (2-5). In association with improvements in organ preservation and extended donor eligibility, organ transplantation has become an increasingly important and successful component of modern medicine with more than 34,000 transplants performed in the United States alone in 2017 (6). Imaging plays a critical role in organ transplantation as it allows assessment of donors and recipients both before and after transplantation. The growing use of living candidates to meet the demand for organ donors has resulted in frequent imaging of donors

during pre-transplantation assessment. These requests are not restricted solely to tertiary transplant centers given the increasing development of regional and national transplant networks. Identification of donor anatomy, variants and any associated pathology is essential for the selection of appropriate surgical candidates and suitable surgical technique. This process has been facilitated by the improved multimodality protocols and techniques available to radiologists. Detailed knowledge and understanding of these options and protocols is critical to ensuring optimal patient outcomes, and ultimately survival. This article will focus on imaging evaluation of donor candidates for liver and pancreas transplantation.

Liver transplantation

First described in 1968, liver transplantation has since

become the definitive treatment for end-stage liver disease in suitable recipient candidates (3). As a result, the number of LTs has increased substantially, with 8082 transplants performed in 2017 in the United States (US) compared to 1713 in 1988 according to the United Network for Organ Sharing (UNOS) (7). While living donor liver transplantation (LDLT) has become an increasingly accepted alternative to deceased donors over this period, it still only accounted for 11.5% of LTs in the US in 2014–2016, compared to 0% in 1988 (7-11). However, almost 14,000 candidates remain on the LT waiting list in the US as of May 2018 (12).




Figure 1 Segmental hepatic anatomy. This image illustrates the segmental hepatic anatomy and its relationship with the portal venous (light blue) and hepatic arterial (red) inflow anatomy, as well as the draining hepatic venous (dark blue) and biliary (green) systems.

Types of liver transplantation

Depending on the nature of the organ used, liver transplantation broadly includes deceased donor transplantation and LDLT (13). Evaluation of the donor liver requires a knowledge of the segmental anatomy of the liver (*Figure 1*).

Deceased donor transplant

The most commonly performed LT surgical technique involves the replacement of the native liver with a donor liver from a deceased donor. LT can involve the transplant of the whole donor liver into one recipient, or a split liver transplant (SLT), whereby one donor liver is split into independent anatomical segments to allow for two recipients to be transplanted (11). SLT evolved from techniques developed to resize adult donor livers for pediatric recipients (14) and has been considered a means of expanding the donor pool in the context of a limited donor organ supply (15-17). SLT accounted for 1.2% of LT in adults in the US in 2016 (11).

The splitting of the donor liver into separate grafts can be performed in the donor prior to procurement or as a back-table procedure after retrieval, known as *in situ* and *ex vivo* techniques, respectively (18). The original technique allowed for the transplant of a child and adult, with the liver split along the falciform ligament into a left lateral segment incorporating segments II and III for the child and a larger tri-segment which includes segments I, IV, V, VI, VII and VIII for the adult (*Figure 2A*) (19). Subsequent advances have led to the development of a technique that allows for the creation of two comparably sized grafts, one




Figure 2 Deceased donor liver transplantation. (A) The donor liver can be transected along the falciform ligament to create a small graft incorporating segments II and III for a pediatric recipient, and a larger graft incorporating segments I, IV, V, VI, VII and VIII for an adult recipient; (B) the donor liver can be transected approximately along the middle hepatic vein to create two equal grafts involving segments I–IV and V–VIII. IVC, inferior vena cava; RHV, right hepatic vein; MHV, middle hepatic vein; LHV, left hepatic vein; LHA, left hepatic artery; HA, hepatic artery; RHA, right hepatic artery; LPV, left portal vein; PV, portal vein; RPV, right portal vein; CBD, common bile duct.




Figure 3 Living donor liver transplantation: depending on the clinical requirements, left (A) or right (B) lobe grafts can be created based on the transection plane along or near the middle hepatic vein.

including segments I–IV and the other segments V–VIII. The conventional dissection plane is made to the right of, or along, the middle hepatic vein (MHV) given the smaller volume of the left liver lobe, but alternative approaches and reconstructive techniques have been described in the literature (*Figure 2B*) (20–23).

Living donor liver transplant

LDLT involves removal of a portion of healthy liver from a matched donor and placement into a recipient. Current techniques and expertise result in an overall donor complication rate of 40%, a major donor complication rate of 1.3% and mortality rate of 0.2% (24–26). The critical factor to be considered when contemplating a LDLT is the health of the donor and that sufficient residual liver volume remains in the donor to avoid donor liver failure after hepatectomy. Sufficient residual liver volume should be at least 30–35% of the donor's total liver volume depending on the quality of the underlying liver parenchyma (24,27,28). Ensuring that the graft weight/recipient body weight ratio (GWBWR) remains greater than 0.8% is also critical to minimize the risk of the recipient developing small for size syndrome (SFSS) (29). Both considerations influence the approach and technique to the donor hepatectomy.

If a graft is required for a pediatric recipient, a left lateral segmentectomy along the falciform ligament to include segments II and III can be performed as described for the deceased donor graft procurement. An alternate approach for an adult recipient includes a full left hepatectomy with the transection margin passing to the left of, or including, the MHV and sometimes segment I (*Figure 3A*). However, to avoid SFSS in the recipient, a full right hepatectomy is

also a consideration, which involves segment V, VI, VII and VIII, and sometimes segment I (*Figure 3B*). This transection occurs along the MHV which is sometimes included in the donor graft depending on the risk to the donor (8,27,30).

Liver donor: imaging evaluation

Organ Procurement and Transplantation Network (OPTN) donor evaluation includes anatomical assessment of certain living liver donor parameters; projected graft volume, the donor's remnant volume, vascular anatomy and determination of hepatic steatosis (31). This is predicated on the fact that up to 11% of potential LDLT donor candidates have been shown to be excluded from consideration for anatomic reasons (32), while another study found that 38% of donor candidates were excluded in total (33). Tailored multidetector computed tomography (MDCT) (*Table 1*) and magnetic resonance imaging (MRI) (*Table 2*) studies can be performed to achieve a comprehensive assessment of the donor anatomy (*Table 3*) (31).

Multiphase contrast-enhanced CT provides improved spatial resolution relative to MRI, permitting evaluation of the liver parenchyma itself. A sample multiphase protocol includes a limited non-contrast phase incorporating four 10 mm slices of the mid liver to allow for hepatic steatosis evaluation, an arterial phase of the whole liver with image acquisition triggered by bolus tracking from a region of interest over the aorta to evaluate the arterial anatomy and a portal venous phase of the whole liver acquired 60 seconds after contrast injection to assess the portal and hepatic venous anatomy (*Table 1*). Both post-contrast phases play a role in assessing for focal liver lesions. Isotropic MDCT data can be post-processed as necessary to allow for the

Table 1 Sample protocol for CT evaluation of a liver transplant donor candidate

Contrast	
Oral contrast	Water
Intravenous contrast	
Iodinated contrast (370 mg/mL)	110 mL
Flush (0.9% NaCl)	40 mL
Rate	4 mL/sec
CT protocol	
Non-contrast abdomen	
Field of view	4 slices mid liver
Thickness	10 mm
Pitch	1.375
Interval	10 mm
kV	120
Auto millampere (mA)	
<200 pounds (lbs)	150–250
>200 pounds (lbs)	150–350
Arterial phase	
Bolus tracking ROI (aorta)	First cut of scan
HU threshold	150
Field of view	Entire liver
Thickness	1.25 mm
Pitch	1.375
Interval	0.625 mm
kV (<200 lbs/>200 lbs)	100/120
Auto mA	150–450
Portal venous phase	
Delay	60 seconds after injection
Field of view	Entire liver
Thickness	2.5 mm
Pitch	1.375
Interval	2.5 mm
kV	120
Auto mA	75–450

creation of three-dimensional (3-D) image construction, maximum intensity projection and volume rendering. In addition, it allows for more accurate characterization of the hepatic vasculature [hepatic arteries (HAs), portal veins (PVs) and hepatic veins (HVs)] (37).

Dual energy CT (DECT) is now increasingly established in mainstream radiology practice since its commercial release in 2006 (38,39). It has been shown to improve the conspicuity of hypovascular liver metastases, as well as improved diagnostic accuracy and characterization of hypervascular liver lesions (39). In addition, the development of improved virtual enhanced images, as well as a reduced intravenous iodinated contrast requirement, may in future help to reduce donor radiation exposure (40,41).

Newer MRI techniques acquired over shorter periods allow for increasing spatial resolution in studies without any associated radiation exposure to the donor. The availability of hepatobiliary contrast agents also permits the delineation of biliary anatomy, which is particularly important given the discontinuation of the CT cholangiographic contrast agent, iodipamide meglumine (42). These agents, including gadoxetate disodium and gadobenate dimeglumine, allow for sensitivity and specificity of up to 88% and 93% respectively when combined with heavily T2 weighted 2D and reconstructed 3D maximum intensity projection magnetic resonance cholangiograms (43,44). Given the equivalent biliary image quality associated with both agents, gadoxetate disodium (Eovist; Bayer AG, Leverkusen, Germany) is increasingly favored due to its shorter hepatobiliary phase image acquisition timing of 10–20 minutes versus up to 60 minutes for gadobenate dimeglumine (34,45). The use of post-processing MRI techniques, such as multiplanar reconstruction (MPR), allows for the creation of clear images which can be of assistance in defining the anatomy and surgical planning (*Figure 4*).

In the context of MRI utilization, radiologists must remain cognizant of the consequences of gadolinium administration. While the incidence of adverse reactions is reported to be 0.01–2.4%, lower than that associated with iodinated CT contrast agents, and with an exceedingly low mortality rate of 0.00008% to 0.0019% (46), the use of gadolinium in those patients with renal impairment remains controversial. Nephrogenic system fibrosis (NSF) is a systemic fibrosing process with high morbidity and mortality first described in 1997 and subsequently linked to gadolinium-based contrast agents (GBCAs) in 2006 (47). It is most closely linked with the use of certain linear non-ionic GBCA in the setting of renal dysfunction, either chronic kidney disease (CKD) or acute

Table 2 Sample protocol for MRI evaluation of a liver transplant donor candidate

Contrast		
Intravenous contrast	Gadoxetate disodium	10 mL
	Flush (0.9% NaCl)	15 mL
Rate		1.0 mL/sec
MR protocol		
Triplanar localizers	T2	2D single shot echo-planar FSE non-BH 2D single shot echo-planar FSE BH
Coronal	T2	2D Single shot echo-planar FSE non-BH 2D Balanced steady-state GRE
Axial	In phase/out of phase	3D DualEcho BH
	Dixon method imaging	Spoiled gradient recalled echo
	Diffusion-weighted imaging	2D Spin echo
	Apparent diffusion coefficient	
Coronal oblique	Thick slab MRCP	2D spin echo
	3D MRCP	3D fast relaxation FSE
Axial	3D T1 FS	3D spoiled GRE pulse sequence
	3D T1 FS post-contrast	Dynamic 3D spoiled gradient recalled echo (5 phases) post IV contrast injection
	3D T1 FS post-contrast	3D spoiled GRE pulse sequence BH 70 seconds post IV contrast injection
	3D T1 FS post-contrast	3D spoiled GRE pulse sequence BH 180 seconds post IV contrast injection
	T2	2D single shot echo-planar FSE
Coronal	T2 FS	2D radial sampling method
	3D T1 FS post-contrast	3D spoiled GRE pulse sequence BH 18 minutes post IV contrast injection
	3D T1 FS post-contrast	3D spoiled GRE pulse sequence BH 18 minutes post IV contrast injection
Axial	3D T1 FS post-contrast	3D spoiled GRE pulse sequence BH 25 minutes post IV contrast injection
Coronal	3D T1 FS post-contrast	3D spoiled GRE pulse sequence BH 25 minutes post IV contrast injection

FSE, fast spin echo; BH, breath hold; GRE, gradient echo; MRCP, magnetic resonance cholangiopancreatography; MIP, maximum intensity projection; FS, fat saturated.

Table 3 Comparison of efficacy of MRI with gadoxetate disodium and CT with iodinated contrast in the evaluation of liver donor candidates (34-36)

Features assessed	Computed tomography	Magnetic resonance imaging
Hepatic steatosis	Sensitivity: 46–72%	Sensitivity: 77–95%
	Specificity: 88–95%	Specificity: 81–97%
Hepatic arterial anatomy, accuracy %	89–96%	86%
Portal vein anatomy, accuracy %	96–100%	93%
Hepatic vein anatomy, accuracy %	68–86%	68%
Biliary anatomy, accuracy %	N/A	93%

No accuracy is given for CT assessment of biliary anatomy as it is no longer used for this purpose.




Figure 4 Maximum intensity projection (MIP) image in the coronal plane from a magnetic resonance angiogram (MRA) of conventional hepatic arterial anatomy. The common hepatic artery (CHA) is seen arising from the celiac trunk. LHA, left hepatic artery; RHA, right hepatic artery; GDA, gastroduodenal artery; LGA, left gastric artery.

kidney injury (AKI) (48). However since its identification and characterization, NSF has been almost eliminated after changes in the Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory framework (49,50), and subsequently in the European Society of Urogenital Radiology (ESUR) and the American College of Radiology (ACR) guidelines (51,52), resulting in the withdrawal or restriction of the GBCAs of concern and more rigorous evaluation of contrast use in those patients with renal impairment. An ongoing discussion centers on the recently established entity of gadolinium deposition within bone and the central nervous system (CNS), even in the absence of renal impairment or increased blood-brain barrier permeability (53-58). Recent studies have also demonstrated a relationship between the degree of deposition and the numbers of doses and types of GBCAs, particularly linear agents, administered (59). Despite an updated FDA Drug Safety Communication being issued in May 2018 (60), no adverse consequences to tissue deposition of gadolinium have been identified but clinical discretion regarding the judicious use of GBCAs remains important (51).

Hepatic parenchymal evaluation

Imaging of the donor hepatic parenchyma should allow

for evaluation for both focal and diffuse hepatic processes. The incidence of hepatic steatosis (HS) amongst donor candidates has been estimated at 25% (61). Moderate-severe HS (30–60% hepatic steatosis) in deceased donor livers is associated with decreased graft survival, while severe HS (>60% hepatic steatosis) is associated with an increased risk of poor graft function and primary graft non-function requiring re-transplantation (62,63). Recipient outcomes using grafts with varying fatty infiltration beneath 30% do not vary significantly and therefore, deceased donor grafts with greater than 30% fatty infiltration are not commonly considered (64-66), while this threshold falls to 10–15% for LDLT grafts at most centers (67). A further influencing factor limiting use of moderate-severe HS LDLT grafts is the increased perioperative mortality and morbidity associated with major hepatectomies (68), and the additional risk to the donor. While liver biopsy remains the gold standard for assessment of HS, it still carries complication and mortality rates of 0.6% and 0.03% respectively (69), and therefore non-invasive assessment is preferred in living donors. CT can be used to quantify moderate-severe HS by a number of means; an absolute liver parenchymal attenuation less than 40 Hounsfield Units (HU), a liver/spleen attenuation ratio of less than 0.8, both on a non-contrast CT, an attenuation of 10 HU or greater less the spleen (35,70,71). Overall, CT demonstrates high accuracy in detecting moderate-severe HS in liver donors (72) but is less effective in quantitative assessment of HS (73). MRI Dixon-based protocols which demonstrate 30% signal drop out on the out of phase sequences relative to in phase sequences normalized to spleen have been shown to effectively differentiate mild-moderate HS from moderate-severe HS (34,74,75). In addition to hepatic steatosis, it is important not to overlook any other parenchymal abnormality such as hemochromatosis, or a focal liver lesion (FLL), such as a cyst, hemangioma, hepatic adenoma or focal nodular hyperplasia. In a cohort of LDLT donors assessed with CT, 25% were shown to have a FLL (76), while a similar study with MR showed 29% with FLL (77), however all were benign. Depending on location and size, diffuse or focal processes can exclude a potential donor from consideration.

Liver volumetry

In LDLT scenarios, liver volumes are calculated to ensure that sufficient liver will be available to both the donor




Figure 5 Michels classification of hepatic artery variant anatomy and their incidence (Michels, 1966) (83). LHA, left hepatic artery; RHA, right hepatic artery.

and graft to the recipient to prevent donor liver failure and SFSS in the recipient respectively. Both MRI and MDCT can both be used to calculate volumes as long as there is sufficient tissue contrast and minimal movement artifact (34), with both producing safe estimates (37,78,79). Precise delineation of the transection planes is particularly important in the setting of right liver lobe donation given the absence of clear anatomical landmarks (80).

Vascular evaluation

Assessment of hepatic vascular anatomy in the donor is very important for optimal donor performance after hepatectomy and successful liver transplantation in the recipient. Only 35% of the population has been shown

to possess conventional HA, HV and PV anatomy, with variant HA and HV each found in 40% of the population, and variant PV anatomy found in 20% (81). Therefore, knowledge and awareness of variant hepatic vasculature is critical in liver donor evaluation and surgical planning.

Hepatic arterial anatomy

Conventional hepatic arterial anatomy (HAA) is defined as a common hepatic artery arising from the celiac axis supplying the whole liver through right and left hepatic arteries, resulting from normal hepatic embryological development (Figure 4) (82). This normal anatomical configuration has been reported in as low as 55% of the population (83,84). The Michels Classification describes ten anatomic variant categories (Figure 5), but only a subset

Table 4 Relevant hepatic artery variant anatomy and the impact on surgical retrieval or implantation techniques

Hepatic artery variant	Surgical implication
Location of segment IV artery/MHA	If performing right hepatectomy, important to preserve MHA if arising from RHA as required for left lobe regeneration MHA point of origin is important to identify as its preservation in the donor in right hepatectomy can lead to short RHA in the graft for anastomosis to the recipient If performing left hepatectomy and MHA arising from RHA, separate anastomoses with the recipient necessary for LHA and MHA
Accessory/replaced LHA/RHA	Additional donor ligation/recipient anastomosis
CHA trifurcation/origin of RHA or LHA from CHA before origin of GDA	Impairment of gastric/duodenal arterial supply in donor may result from clamping/ligating CHA

MHA, middle hepatic artery; LHA, left hepatic artery; RHA, right hepatic artery; CHA, common hepatic artery; GDA, gastroduodenal artery.




Figure 6 MIP image in the coronal plane from a MRA of a replaced common hepatic artery (arrow) arising from the superior mesenteric artery (SMA, +) with the abdominal aorta visible proximally (*). MIP, maximum intensity projection; MRA, magnetic resonance angiogram.



Figure 7 Superior mesenteric artery (SMA) angiogram demonstrating a replaced right hepatic artery (RRHA, arrow) arising from the SMA (*).

of these are surgically relevant for donor LT evaluation and are outlined in *Table 4* (81,85,86). Accessory HAs are variant arteries present in addition to the conventional HAA while replaced HAs are present in place of the conventional HAA (*Figures 6,7*). An important variation not covered by the Michels Classification is the origin of the segment IV HA or middle hepatic artery (MHA), a relevant finding for both right and left donor hepatectomy donor candidates (87). These anatomical variants are most relevant in living donors where arterial supply to both the graft and the remnant liver has to be fully maintained.

They also are important in deceased donors, to determine the possibility of splitting the liver into two grafts if that was intended, and, in the case of a full liver graft, to determine the arterial reconstruction required to maintain arterial supply. This reconstruction is often performed *ex-vivo* prior to implanting the graft.

Portal venous anatomy

Conventional PV anatomy (PVA) has been reported in 65–80% of the population, but up to a fifth of donor candidates have been excluded from consideration due to PVA




Figure 8 The most common portal venous anatomical variants and their incidence (Covey *et al.*, 2004) (89). MPV, main portal vein; LPV, left portal vein; RPV, right portal vein; ARPV, anterior right portal vein; PRPV, posterior right portal vein.

Table 5 Relevant portal venous variant anatomy and the impact on surgical retrieval or implantation techniques

Portal vein variant	Surgical implication
Absence of RPV/MPV Trifurcation into LPV, ARPV and PRPV	If performing right hepatectomy, will need to transect both the ARPV and PRPV separately and perform separate anastomoses with recipient PV If performing left hepatectomy, must leave ARPV intact in donor liver
ARPV arising from LPV	May be contraindication to left donor hepatectomy, as transection plane distal to ARPV origin leaves too little LPV length for anastomosis to recipient Complicates right donor hepatectomy as requires anastomosis of the ARPV and PRPV in the recipient, usually performed prior to implantation
LPV arising from RPV	May be contraindication to right donor hepatectomy, as donor ARPV then too short for anastomosis to recipient as transection margin must preserve LPV in donor

RPV, right portal vein; MPV, main portal vein; LPV, left portal vein; ARPV, anterior right portal vein; PRPV, posterior right portal vein; PV, portal vein.

variants (84,88,89) (Figure 8). Conventional PVA describes the main portal vein (MPV) formed by the confluence of the splenic vein (SV) and superior mesenteric vein (SMV) before it branches into the right portal vein (RPV) and left portal vein (LPV) at the hilum. The RPV then divides into anterior RPV (ARPV) which supplies segments V and VIII, and the posterior RPV (PRPV) which supplies segments VI and VII. The LPV supplies segments II, III and IV, and

branches from both the RPV and LPV supply segment I (90). PV anatomical variants of surgical relevance are detailed in Table 5 (Figures 9,10) (85). Additional surgical considerations are the angle of the MPV bifurcation, with too small an angle allowing for possible compromised portal vein supply in the recipient of whole livers as the donor liver hypertrophies and encases both the RPV and LPV, as well as the length of the MPV and its diameter at the



Figure 9 Axial oblique image of a portal venous phase CT demonstrating an anterior right portal vein (arrow) arising from the left portal vein (*).

anticipated site of anastomosis, both of which also influence surgical technique (91).

Hepatic venous anatomy

Normal HV anatomy is seen in up to 70% of the population and describes three hepatic veins; the right hepatic vein (RHV) draining segments V, VI, VII and VIII, the MHV draining segments IV, V and VIII, and the left hepatic vein (LHV) draining segments II and III, with segment I draining directly into the inferior vena cava (IVC) (Figure 11) (84,93). Approximately 60% of patients demonstrate common drainage of the LHV and MHV into the IVC. Surgically relevant HV anatomical variants are detailed in Table 6 (92). Pre-operative identification of accessory HVs in the donor is important to minimize excessive bleeding during the transplant hepatectomy, while accurate estimation of their distance from the HV/IVC confluence permits accurate surgical planning as a distance greater than 4 cm often precludes a single anastomosis with the conventional donor HV to the recipient IVC (Figures 12,13) (94). Accessory HVs smaller than 0.3 cm in diameter can be ligated with minimal risk of graft congestion (85). The most common accessory HV, an accessory inferior RHV draining predominantly segments VI and VII directly into the IVC, can be present in up to 47% of donors, while variant segment VIII drainage via a separate accessory vein is seen in 9% (81,87).

Location and orientation of the HV anatomy is critically important, as the transection plane for a right hepatectomy in LDLT is usually positioned 1.0 cm to the right of the




Figure 10 Axial oblique image of a portal venous phase CT demonstrating a trifurcation of the main portal vein (MPV) into the left portal vein (LPV) and the two branches of the right portal vein (RPV), the anterior and posterior right portal veins.

MHV. Pre-operative knowledge of accessory hepatic veins within the donor graft are essential as failure to identify and anastomose these vessels to the recipient structures can potentially lead to hepatic parenchymal congestion, graft failure and/or parenchymal atrophy (81,85).

Biliary anatomy

Conventional biliary anatomy is seen in approximately 60–70% of the population (Figures 14,15) (95–99). This describes a right hepatic duct (RHD), comprised of an anterior right hepatic duct (ARHD) draining segments V and VIII and a posterior right hepatic duct (PRHD) draining segments VI and VII, joining with a left hepatic duct (LHD) which drains segments II, III and IV to form a common hepatic duct (CHD). Segment I drains into the more central segments of the LHD or RHD. The cystic duct then joins with the CHD to form the common bile duct (CBD). Biliary duct complications occur in 10–25% of recipients and up to 1.8% of donors (85,100). The risk of biliary complications is increased with the number of anastomoses, HA thrombosis and small hepatic duct caliber (101,102). Bile duct strictures are the most common recipient complication in LT, causing around 40% of all biliary complications, and are seen in up to 5% of deceased donor LT and between 7.4–60% of LDLT depending on the type of donor hepatectomy performed (103). Normal anatomy allows for an uncomplicated single duct-to-duct anastomosis but appropriate pre-operative donor evaluation and tailored surgical techniques allow for the risk of biliary complications to be minimized (104). The relevant biliary




Figure 11 The most common hepatic vein anatomical variants and their incidence (Varotti *et al*, 2004) (92). IRHV, inferior right hepatic vein; S5, vein draining segment V; S8, vein draining segment VIII.

Table 6 Relevant hepatic vein variant anatomy and the impact on surgical retrieval or implantation techniques

Hepatic vein variant	Surgical implication
Accessory inferior RHV from segment V/VI/VII draining directly IVC	Important to recognize as this may influence donor right hepatectomy technique to avoid excessive hemorrhage, as well as transplant technique given need for separate recipient anastomosis for graft drainage to avoid congestion, especially in smaller size grafts (GWBWR <1%)
Late confluence of MHV tributaries	Can influence transection plane for right hepatectomies as well as requiring separate anastomoses for branches draining segments V and VIII
Early confluence of HV	Increased risk of recipient SFSS, and may be a contraindication to transplant
Patency and anatomy of HV draining segment IV	If thrombosed or occluded during donor left hepatectomy, can lead to graft congestion and/or atrophy If draining into MHV in donor right hepatectomy candidate, can include MHV in graft as not required for remnant liver drainage
Common drainage of MHV and LHV into IVC	Important to preserve MHV <i>in situ</i> in donor when performing left lateral segmentectomy
MHV draining majority of right liver lobe either due to direct right liver lobe tributaries or small RHV	If considering donor right hepatectomy, individual anastomoses of draining tributaries to recipient may be required If considering donor left hepatectomy, left lateral segmentectomy may be preferable to ensure preservation of the donor MHV <i>in situ</i>

RHV, right hepatic vein; IVC, inferior vena cava; MHV, middle hepatic vein; LHV, left hepatic vein; GWBWR, graft weight/recipient body weight ratio.



Figure 12 MIP image in the axial plane from a portal venous phase CT of conventional hepatic vein anatomy. MIP, maximum intensity projection.




Figure 13 Coronal image of a portal venous phase CT demonstrating an accessory/inferior right hepatic vein (arrow) from segment VI draining into the inferior vena cava (*) inferior to the main right hepatic vein (triangle).

anatomy variants are described in *Table 7*.

Often overlooked in the overall liver donor evaluation process is the importance of effective, accurate, reproducible and succinct communication of the radiologist's findings to the transplant surgeon and hepatologist. To facilitate this process, the use of structured reporting can be of benefit, providing for effective communication and referring physician satisfaction (105,106). This also helps to ensure that all relevant information is included in reports, reduces the risk for oversights or errors and ensures that critical findings are conveyed to the referrer (107-109).




Figure 14 Coronal 2D magnetic resonance cholangiopancreatogram image demonstrating conventional biliary anatomy. LHD, left hepatic duct; RHD, right hepatic duct; ARHD, anterior right hepatic duct; PRHD, posterior right hepatic duct.

Pancreatic transplantation

Achieving normoglycemia in insulin-dependent diabetic patients is the primary indication for pancreas transplant (PT), first performed in 1966, with the secondary benefit of limiting the sequelae of uncontrolled diabetes, such as diabetic nephropathy and retinopathy (110-112). While not performed as frequently as LTs, PTs are increasingly performed with 213 performed in the United States in 2017 compared to 78 in 1988, all of which were from deceased donors (7). 75% of PTs are performed simultaneously with kidney transplants, known as simultaneous pancreas-kidney (SPK) transplants, with pancreas after kidney (PAK) transplants and pancreas transplants alone (PTA) making up the remainder with 18% and 7% respectively (113). Given the lack of living donors, imaging plays no formal role in pre-transplant donor evaluation, with intra-operative appraisal by the transplant surgeon the most important assessment (114). However in limited situations, prior imaging of a deceased donor may be available for review and knowledge of the surgical techniques used and salient vascular anatomy may be beneficial if the radiologist's opinion is sought (*Figure 16*). The graft can also be assessed for fibrosis, fatty infiltration and calcification.

The donor pancreas is procured with the adjacent duodenal stump including the ampulla of Vater and local vasculature, as well as the donor common, internal and external iliac arteries in continuity, to allow the creation of an arterial Y graft (115). The Y graft is used to anastomose the donor superior mesenteric artery (SMA) to the donor external iliac artery to supply the pancreatic head, and the internal iliac artery to the splenic artery to supply the




Figure 15 The most common biliary anatomical variants and their incidence (Brunicardi *et al*, 2014) (95). RHD, right hepatic duct; LHD, left hepatic duct; PRHD, posterior right hepatic duct; ARHD, anterior right hepatic duct.

Table 7 Relevant biliary variant anatomy and the impact on surgical retrieval or implantation techniques

Biliary variant	Surgical implication
Presence of any accessory HD	Important to identify as influences surgical technique for both right or left hepatectomies
Segment IV HD	If considering donor right hepatectomy, should be preserved in donor
Common origin of the LHD, PRHD and ARHD	Influences surgical technique and increases complexity of approach to transplant
ARHD/PRHD draining into LHD	Excludes donor from left lobe donation More challenging right lobe donor hepatectomy technique
LHD draining into ARHD/PRHD	Excludes donor from right lobe donation More challenging left lobe donor hepatectomy technique

HD, hepatic duct; LHD, left hepatic duct; PRHD, posterior right hepatic duct; ARHD, anterior right hepatic duct.

pancreatic body and tail. The donor common iliac artery is then anastomosed to a recipient common or external iliac artery to facilitate arterial blood supply to the graft. The donor portal vein is also resected intact to facilitate superior mesenteric and splenic vein drainage, and this is anastomosed to the recipient superior mesenteric vein (SMV) or an iliac vein in portal or systemic venous techniques respectively (116-118).

The two most prevalent surgical techniques in use currently include systemic venous-enteric exocrine drainage




Figure 16 Schematic diagram of conventional pancreatic anatomy.

(*Figure 17A*), where the donor portal vein and recipient common or external iliac vein are anastomosed for systemic venous drainage while the donor duodenum is anastomosed to a recipient jejunal loop to allow for exocrine drainage and portal venous-enteric drainage (*Figure 17B*) where the donor portal vein is anastomosed to the recipient SMV. Rarely used is the bladder drainage of the donor duodenum (*Figure 17C*), given the complications associated with fluid and bicarbonate loss in the urine and cystitis secondary to the pancreatic enzymes effect in the bladder (116-119).

As a result, it may be of some benefit to the radiologist's surgical colleagues if it is possible to establish the patency of the relevant arterial and venous structures on prior imaging, as well as the infrequent presence of relevant SMA variant anatomy, such as a common origin of the celiac trunk and SMA (120).

Conclusions

Imaging plays a critical role in the evaluation of liver donors prior to transplantation allowing for assessment of hepatic parenchymal, biliary and vascular anatomy. Adequate knowledge and understanding of these anatomic considerations is required for radiologists to provide precise information to the surgeons for preoperative planning to enable successful transplantation.




Figure 17 The varying techniques for pancreatic transplant. (A) Systemic venous-enteric exocrine drainage, (B) portal venous-enteric drainage and (C) systemic venous-bladder exocrine drainage. D, duodenum; PV, portal vein; SMV, superior mesenteric vein; SA, splenic artery; SV, splenic vein; CIA, common iliac artery; CIV, common iliac vein; YG, Y graft ('d', donor; 'r', recipient).

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

- Harrison JH, Merrill JP, Murray JE. Renal homotransplantation in identical twins. *Surg Forum* 1956;6:432-6.
- Dangoor JY, Hakim DN, Singh RP, et al. Transplantation: a brief history. *Exp Clin Transplant* 2015;13:1-5.
- Starzl TE, Groth CG, Brettschneider L, et al. Orthotopic homotransplantation of the human liver. *Ann Surg* 1968;168:392-415.
- Starzl TE, Porter KA, Putnam CW, et al. Orthotopic liver transplantation in ninety-three patients. *Surg Gynecol Obstet* 1976;142:487-505.
- Porrett PM, Hashmi SK, Shaked A. Immunosuppression: trends and tolerance? *Clin Liver Dis* 2014;18:687-716.
- Sharing UNfO. Transplant trends. In: United Network for Organ Sharing, 2018.
- Sharing UNfO. Transplant trends. In: United Network for Organ Sharing: United Network for Organ Sharing, 2017.
- Tulla KA, Jeon H. Living Donor Liver Transplantation: Technical Innovations. *Gastroenterol Clin North Am* 2018;47:253-65.
- Yamaoka Y, Washida M, Honda K, et al. Liver transplantation using a right lobe graft from a living related donor. *Transplantation* 1994;57:1127-30.
- Vagefi PA, Ascher NL, Freise CE, et al. Use of living donor liver transplantation varies with the availability of deceased donor liver transplantation. *Liver Transpl* 2012;18:160-5.
- Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 Annual Data Report: Liver. *Am J Transplant* 2018;18 Suppl 1:172-253.
- Network OPaT. National Data. In: U.S. Department of Health & Human Services, 2018.
- Eghtesad B, Kadry Z, Fung J. Technical considerations in liver transplantation: what a hepatologist needs to know (and every surgeon should practice). *Liver Transpl* 2005;11:861-71.
- Bismuth H, Houssin D. Reduced-sized orthotopic liver graft in hepatic transplantation in children. *Surgery* 1984;95:367-70.
- Busuttil RW, Goss JA. Split liver transplantation. *Ann Surg* 1999; 229:313-21.
- Halac E, Dip M, Quinonez E, et al. Split liver transplantation: Report of right and left graft outcomes from a multicenter Argentinean group. *Liver Transpl* 2016;22:63-70.
- Vagefi PA, Parekh J, Ascher NL, et al. Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010. *Arch Surg* 2011;146:1052-9.
- Liu H, Li R, Fu J, et al. Technical Skills Required in Split Liver Transplantation. *Ann Transplant* 2016;21:408-15.
- Hashimoto K, Fujiki M, Quintini C, et al. Split liver transplantation in adults. *World J Gastroenterol* 2016;22:7500-6.
- Vagefi PA, Parekh J, Ascher NL, et al. Ex vivo split-liver transplantation: the true right/left split. *HPB (Oxford)* 2014; 16:267-74.
- Emre S, Umman V. Split liver transplantation: an overview. *Transplant Proc* 2011;43:884-7.
- Ferla F, Lauterio A, Di Sandro S, et al. Split-liver full-left full-right: proposal for an operative protocol. *Transplant Proc* 2014;46:2279-82.
- Sguinzi R, Ferla F, De Carlis R, et al. Split liver technique with middle hepatic vein reconstruction on livers from transplant hepatectomies: a useful tool for surgical improvement. *Updates Surg* 2018;70:491-4.
- Hwang S, Lee SG, Lee YJ, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. *Liver Transpl* 2006;12:920-7.
- Fisher RA. Living donor liver transplantation: eliminating the wait for death in end-stage liver disease? *Nat Rev Gastroenterol Hepatol* 2017;14:373-82.
- Abecassis MM, Fisher RA, Olthoff KM, et al. Complications of living donor hepatic lobectomy--a comprehensive report. *Am J Transplant* 2012;12:1208-17.
- Lee SG. A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients. *Am J Transplant* 2015;15:17-38.
- Marcos A, Ham JM, Fisher RA, et al. Single-center analysis of the first 40 adult-to-adult living donor liver transplants using the right lobe. *Liver Transpl* 2000;6:296-301.
- Hill MJ, Hughes M, Jie T, et al. Graft weight/recipient weight ratio: how well does it predict outcome after partial

- liver transplants? *Liver Transpl* 2009;15:1056-62.
30. Jung DH, Hwang S, Song GW, et al. In Situ Split Liver Transplantation for 2 Adult Recipients: A Single-Center Experience. *Ann Transplant* 2017;22:230-40.
 31. Network OPaT. Organ Procurement and Transplantation Network Policies. In: *Organ Procurement and Transplantation Network*, 2018.
 32. Tsang LL, Chen CL, Huang TL, et al. Preoperative imaging evaluation of potential living liver donors: reasons for exclusion from donation in adult living donor liver transplantation. *Transplant Proc* 2008;40:2460-2.
 33. Hahn LD, Emre SH, Israel GM. Radiographic features of potential donor livers that precluded donation. *AJR Am J Roentgenol* 2014;202:W343-8.
 34. Jhaveri KS, Guo L, Guimaraes L. Current State-of-the-Art MRI for Comprehensive Evaluation of Potential Living Liver Donors. *AJR Am J Roentgenol* 2017;209:55-66.
 35. Zhang YN, Fowler KJ, Hamilton G, et al. Liver fat imaging - a clinical overview of ultrasound, CT, and MR imaging. *Br J Radiol* 2018;91:20170959.
 36. Lee MW, Lee JM, Lee JY, et al. Preoperative evaluation of the hepatic vascular anatomy in living liver donors: comparison of CT angiography and MR angiography. *J Magn Reson Imaging* 2006;24:1081-7.
 37. Schroeder T, Malago M, Debatin JF, et al. "All-in-one" imaging protocols for the evaluation of potential living liver donors: comparison of magnetic resonance imaging and multidetector computed tomography. *Liver Transpl* 2005;11:776-87.
 38. McCollough CH, Leng S, Yu L, et al. Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications. *Radiology* 2015;276:637-53.
 39. Lestra T, Mule S, Millet I, et al. Applications of dual energy computed tomography in abdominal imaging. *Diagn Interv Imaging* 2016;97:593-603.
 40. Chung YE, You JS, Lee HJ, et al. Possible Contrast Media Reduction with Low keV Monoenergetic Images in the Detection of Focal Liver Lesions: A Dual-Energy CT Animal Study. *PloS One* 2015;10:e0133170.
 41. De Cecco CN, Muscogiuri G, Schoepf UJ, et al. Virtual unenhanced imaging of the liver with third-generation dual-source dual-energy CT and advanced modeled iterative reconstruction. *Eur J Radiol* 2016;85:1257-64.
 42. Administration USFaD. FDA Drug Shortages. In: U.S. Department of Health and Human Services, 2018.
 43. Artioli D, Tagliabue M, Aseni P, et al. Detection of biliary and vascular anatomy in living liver donors: value of gadobenate dimeglumine enhanced MR and MDCT angiography. *Eur J Radiol* 2010;76:e1-5.
 44. Lewis S, Vasudevan P, Chatterji M, et al. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors. *Abdom Radiol (NY)* 2016;41:1300-9.
 45. Lee MS, Lee JY, Kim SH, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI. *J Magn Reson Imaging* 2011;33:149-59.
 46. Ramalho M, Ramalho J. Gadolinium-Based Contrast Agents: Associated Adverse Reactions. *Magn Reson Imaging Clin N Am* 2017; 25:755-64.
 47. Kaewlai R, Abujudeh H. Nephrogenic systemic fibrosis. *AJR Am J Roentgenol* 2012;199:W17-23.
 48. Daftari Besheli L, Aran S, Shaqdan K, et al. Current status of nephrogenic systemic fibrosis. *Clinical radiology* 2014;69:661-8.
 49. Administration FaD. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. In: Silver Spring M, ed.: Federal Drug Administration, 2010.
 50. European Medicines Agency. Questions and answers on the review of gadolinium-containing contrast agents. 2010:3. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500015635.pdf
 51. Radiology ACo. ACR Manual on Contrast Media Version 10.3, 2018.
 52. Radiology ESoU. 10.0 Contrast Media Safety Guidelines, 2018.
 53. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging. *Radiology* 2015;275:772-82.
 54. Kanda T, Fukusato T, Matsuda M, et al. Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. *Radiology* 2015;276:228-32.
 55. Kanda T, Osawa M, Oba H, et al. High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. *Radiology* 2015;275:803-9.
 56. Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. *Invest*

- Radiol 2004;39:138-42.
57. Kanda T, Ishii K, Kawaguchi H, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. *Radiology* 2014;270:834-41.
 58. McDonald RJ, McDonald JS, Kallmes DF, et al. Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities. *Radiology* 2017;285:546-54.
 59. Kang H, Hii M, Le M, et al. Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents. *AJNR Am J Neuroradiol* 2018;39:1597-603.
 60. Administration FaD. FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. In, 2018.
 61. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. *Semin Liver Dis* 2001;21:105-13.
 62. Chu MJ, Dare AJ, Phillips AR, et al. Donor Hepatic Steatosis and Outcome After Liver Transplantation: a Systematic Review. *J Gastrointest Surg* 2015;19:1713-24.
 63. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. *Liver Transpl* 2010;16:874-84.
 64. McCormack L, Dutkowski P, El-Badry AM, et al. Liver transplantation using fatty livers: always feasible? *J Hepatol* 2011;54:1055-62.
 65. Kwon CH, Joh JW, Lee KW, et al. Safety of donors with fatty liver in liver transplantation. *Transplant Proc* 2006;38:2106-7.
 66. Cho JY, Suh KS, Kwon CH, et al. Mild hepatic steatosis is not a major risk factor for hepatectomy and regenerative power is not impaired. *Surgery* 2006;139:508-15.
 67. Zazos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. *World J Gastroenterol* 2014;20:15532-8.
 68. Behrns KE, Tsiotos GG, DeSouza NF, et al. Hepatic steatosis as a potential risk factor for major hepatic resection. *J Gastrointest Surg* 1998;2:292-8.
 69. Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? *Ann Intern Med* 1993;118:150-3.
 70. Limanond P, Raman SS, Lassman C, et al. Macrovesicular hepatic steatosis in living related liver donors: correlation between CT and histologic findings. *Radiology* 2004;230:276-80.
 71. Cheng YF, Yu CY, Ou HY, et al. Section 1. Image evaluation of fatty liver in living donor liver transplantation. *Transplantation* 2014;97 Suppl 8:S3-6.
 72. Zheng D, Tian W, Zheng Z, et al. Accuracy of computed tomography for detecting hepatic steatosis in donors for liver transplantation: A meta-analysis. *Clin Transplant* 2017;31.
 73. Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. *Radiology* 2006;239:105-12.
 74. Kreft BP, Tanimoto A, Baba Y, et al. Diagnosis of fatty liver with MR imaging. *J Magn Reson Imaging* 1992;2:463-71.
 75. Idilman IS, Aniktar H, Idilman R, et al. Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. *Radiology* 2013;267:767-75.
 76. Schroeder T, Radtke A, Kuehl H, et al. Evaluation of living liver donors with an all-inclusive 3D multi-detector row CT protocol. *Radiology* 2006;238:900-10.
 77. Fulcher AS, Szucs RA, Bassignani MJ, et al. Right lobe living donor liver transplantation: preoperative evaluation of the donor with MR imaging. *AJR Am J Roentgenol* 2001;176:1483-91.
 78. Emiroglu R, Coskun M, Yilmaz U, et al. Safety of multidetector computed tomography in calculating liver volume for living-donor liver transplantation. *Transplant Proc* 2006;38:3576-8.
 79. D'Onofrio M, De Robertis R, Demozzi E, et al. Liver volumetry: Is imaging reliable? Personal experience and review of the literature. *World J Radiol* 2014;6:62-71.
 80. Ishifuro M, Horiguchi J, Nakashige A, et al. Use of multidetector row CT with volume renderings in right lobe living liver transplantation. *Eur Radiol* 2002;12:2477-83.
 81. Erbay N, Raptopoulos V, Pomfret EA, et al. Living donor liver transplantation in adults: vascular variants important in surgical planning for donors and recipients. *AJR Am J Roentgenol* 2003;181:109-14.
 82. Couinaud C. Surgical anatomy of the liver revisited. *Embryology*, 1989.
 83. Michels NA. Newer anatomy of the liver and its variant blood supply and collateral circulation. *Am J Surg* 1966;112:337-47.
 84. Kamel IR, Kruskal JB, Pomfret EA, et al. Impact of multidetector CT on donor selection and surgical planning before living adult right lobe liver transplantation. *AJR Am J Roentgenol* 2001;176:193-200.
 85. Henedige T, Anil G, Madhavan K. Expectations from imaging for pre-transplant evaluation of living donor liver transplantation. *World J Radiol* 2014;6:693-707.

86. Catalano OA, Singh AH, Uppot RN, et al. Vascular and biliary variants in the liver: implications for liver surgery. *Radiographics* 2008;28:359-78.
87. Kamel IR, Kruskal JB, Raptopoulos V. Imaging for right lobe living donor liver transplantation. *Semin Liver Dis* 2001;21:271-82.
88. Sureka B, Patidar Y, Bansal K, et al. Portal vein variations in 1000 patients: surgical and radiological importance. *Br J Radiol* 2015;88:20150326.
89. Covey AM, Brody LA, Getrajdman GI, et al. Incidence, patterns, and clinical relevance of variant portal vein anatomy. *AJR Am J Roentgenol* 2004;183:1055-64.
90. Mathew RP, Venkatesh SK. Liver vascular anatomy: a refresher. *Abdom Radiol (NY)* 2018;43:1886-95.
91. Sahani D, D'Souza R, Kadavigere R, et al. Evaluation of living liver transplant donors: method for precise anatomic definition by using a dedicated contrast-enhanced MR imaging protocol. *Radiographics* 2004;24:957-67.
92. Varotti G, Gondolesi GE, Goldman J, et al. Anatomic variations in right liver living donors. *J Am Coll Surg* 2004;198:577-82.
93. Soyer P, Heath D, Bluemke DA, et al. Three-dimensional helical CT of intrahepatic venous structures: comparison of three rendering techniques. *J Comput Assist Tomogr* 1996;20:122-7.
94. Sahani D, Mehta A, Blake M, et al. Preoperative hepatic vascular evaluation with CT and MR angiography: implications for surgery. *Radiographics* 2004;24:1367-80.
95. Brunicaudi FAD, Billiar TR, Dunn DL, et al. Liver. In: *Principles of Surgery*. McGraw-Hill Professional Publishing, 2014.
96. Mortelé KJ, Ros PR. Anatomic variants of the biliary tree: MR cholangiographic findings and clinical applications. *AJR Am J Roentgenol* 2001;177:389-94.
97. Xu X, Wei X, Ling Q, et al. Inaccurate preoperative imaging assessment on biliary anatomy not increases biliary complications after living donor liver transplantation. *Eur J Radiol* 2012;81:e457-60.
98. Choi JW, Kim TK, Kim KW, et al. Anatomic variation in intrahepatic bile ducts: an analysis of intraoperative cholangiograms in 300 consecutive donors for living donor liver transplantation. *Korean J Radiol* 2003;4:85-90.
99. Macdonald DB, Haider MA, Khalili K, et al. Relationship between vascular and biliary anatomy in living liver donors. *AJR Am J Roentgenol* 2005;185:247-52.
100. Lee JG, Lee KW, Kwon CHD, et al. Donor safety in living donor liver transplantation: The Korean organ transplantation registry study. *Liver Transpl* 2017;23:999-1006.
101. Jeong S, Wang X, Wan P, et al. Risk factors and survival outcomes of biliary complications after adult-to-adult living donor liver transplantation. *United European Gastroenterol J* 2017;5:997-1006.
102. Alawi K, Khalaf H, Medhat Y, et al. Risk factors for biliary complications after living-donor liver transplant: a single-center experience. *Exp Clin Transplant* 2008;6:101-4.
103. Rao HB, Prakash A, Sudhindran S, et al. Biliary strictures complicating living donor liver transplantation: Problems, novel insights and solutions. *World J Gastroenterol* 2018;24:2061-72.
104. Nakamura T, Tanaka K, Kiuchi T, et al. Anatomical variations and surgical strategies in right lobe living donor liver transplantation: lessons from 120 cases. *Transplantation* 2002;73:1896-903.
105. Powell DK, Silberzweig JE. State of structured reporting in radiology, a survey. *Acad Radiol* 2015;22:226-33.
106. Larson DB, Towbin AJ, Pryor RM, et al. Improving consistency in radiology reporting through the use of department-wide standardized structured reporting. *Radiology* 2013;267:240-50.
107. Marcovici PA, Taylor GA. Journal Club: Structured radiology reports are more complete and more effective than unstructured reports. *AJR Am J Roentgenol* 2014;203:1265-71.
108. Hawkins CM, Hall S, Zhang B, et al. Creation and implementation of department-wide structured reports: an analysis of the impact on error rate in radiology reports. *J Digit Imaging* 2014;27:581-7.
109. Buckley BW, Daly L, Allen GN, et al. Recall of structured radiology reports is significantly superior to that of unstructured reports. *Br J Radiol* 2018;91:20170670.
110. Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. *Surgery* 1967;61:827-37.
111. Gruessner RW, Gruessner AC. What defines success in pancreas and islet transplantation-insulin independence or prevention of hypoglycemia? A review. *Transplant Proc* 2014;46:1898-9.
112. Heller MT, Bhargava P. Imaging in pancreatic transplants. *Indian J Radiol Imaging* 2014;24:339-49.
113. Gruessner AC. 2011 update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). *Rev Diabet Stud* 2011;8:6-16.

114. Tolat PP, Foley WD, Johnson C, et al. Pancreas transplant imaging: how I do it. *Radiology* 2015;275:14-27.
115. Gallego Ferrero P, Crespo Del Pozo J. Imaging in pancreas transplantation complications: Temporal classification. *J Med Imaging Radiat Oncol* 2018. [Epub ahead of print].
116. Freund MC, Steurer W, Gassner EM, et al. Spectrum of imaging findings after pancreas transplantation with enteric exocrine drainage: Part 1, posttransplantation anatomy. *AJR Am J Roentgenol* 2004;182:911-7.
117. Fridell JA, Powelson JA, Kubal CA, et al. Retrieval of the pancreas allograft for whole-organ transplantation. *Clin Transplant* 2014;28:1313-30.
118. Vandermeer FQ, Manning MA, Frazier AA, et al. Imaging of whole-organ pancreas transplants. *Radiographics* 2012;32:411-35.
119. Rogers J, Farney AC, Orlando G, et al. Pancreas transplantation with portal venous drainage with an emphasis on technical aspects. *Clin Transplant* 2014;28:16-26.
120. Farghadani M, Momeni M, Hekmatnia A, et al. Anatomical variation of celiac axis, superior mesenteric artery, and hepatic artery: Evaluation with multidetector computed tomography angiography. *J Res Med Sci* 2016;21:129.

Cite this article as: Cahalane AM, Mojtahed A, Sahani DV, Elias N, Kambadakone AR. Pre-hepatic and pre-pancreatic transplant donor evaluation. *Cardiovasc Diagn Ther* 2019;9(Suppl 1):S97-S115. doi: 10.21037/cdt.2018.09.14